SCHEMBL6773755

SCHEMBL6773755

CC(Oc1nn2c(-c3ccc(F)cc3F)nnc2cc1N1CCCC1)c1nc[nH]n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 3/20 0.34
GABRB3 P28472 3/20 0.34
GABRA3 P34903 3/20 0.34
GABRA1 P14867 2/20 0.34
GABRA5 P31644 2/20 0.34
GABRA2 P47869 2/20 0.34
HSD17B10 Q99714 1/20 0.33
PIM1 P11309 1/20 0.33
MAP4K4 O95819 1/20 0.32
EGFR P00533 1/20 0.32
MAPK9 P45984 1/20 0.32
CSNK1D P48730 1/20 0.32
MINK1 Q8N4C8 1/20 0.32
PRKD2 Q9BZL6 1/20 0.32
F2RL1 P55085 3/20 0.32
JAK2 O60674 1/20 0.31
JAK3 P52333 1/20 0.31
HTR1A P08908 1/20 0.30
DRD2 P14416 1/20 0.30
HTR2A P28223 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6772522 0.91 GABRG2 (0.38) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL2648668 0.84 GABRG2 (0.40) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL341951 0.84 GABRG2 (0.36) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL340898 0.84 GABRA1 (0.39) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL6773657 0.83 GABRG2 (0.35) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL340683 0.76 GABRA1 (0.37) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL341874 0.75 GABRA1 (0.44) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL6779561 0.75 GABRA1 (0.46) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL342539 0.75 GABRG2 (0.42) GABRG2GABRB3GABRA3GABRA1GABRA5
SCHEMBL2646554 0.74 GABRG2 (0.39) GABRG2GABRB3GABRA3GABRA1GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2004-04-01 US claimed
US-6828322-B2 Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine MERCK SHARP & DOHME LTD. 2004-12-07 US disclosed
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2004-04-01 US disclosed
US-6579875-B1 Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine MERCK SHARP & DOHME LIMITED 2003-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors GABRA3, GABBR1, GABRA2 GABRG2 15/4885GABRB3 6/4885GABRA3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.